Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs: Clinical Relevance

By Kirchheiner Julia   Roots Ivar   Goldammer Mark   Rosenkranz Bernd  

Clinical Pharmacokinetics, Vol. 44, Iss. 12, 2005-01 ,pp. : 1209-1225

Adis International

Access to resources Recommend Favorite

Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment

By Gschwind Liliane   Rollason Victoria   Boehlen Françoise   Rebsamen Michela   Combescure Christophe   Grünenwald Michèle   Matthey Alain   Bonnabry Pascal   Dayer Pierre   Desmeules Jules Alexandre  

Pharmacogenomics, Vol. 14, Iss. 7, 2013-05 ,pp. : 745-753

Future Medicine

Access to resources Recommend Favorite

Incidence of potential drug-drug interactions with antidiabetic drugs

By Samardzic I.   Bacic-Vrca V.  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 6, 2015-06 ,pp. : 410-415

Govi-Verlag

Access to resources Recommend Favorite

Pharmacogenetic Prediction of Individual Variability in Drug Response Based on CYP2D6, CYP2C9 and CYP2C19 Genetic Polymorphisms

By  

Current Drug Metabolism, Vol. 15, Iss. 7, 2014-09 ,pp. : 711-718

Bentham Science Publishers

Access to resources Recommend Favorite

Prediction of In Vivo Drug-Drug Interactions from In Vitro Data: Factors Affecting Prototypic Drug-Drug Interactions Involving CYP2C9, CYP2D6 and CYP3A4

By Brown Hayley S.   Galetin Aleksandra   Hallifax David   Houston J. Brian  

Clinical Pharmacokinetics, Vol. 45, Iss. 10, 2006-01 ,pp. : 1035-1050

Adis International

Access to resources Recommend Favorite